Rivastigmine Tartrate Capsule
Product Images NDC 65862-649

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 65862-649). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Rivastigmine Fig1)

A line graph showing the time-course change from baseline in ADAS-cog scores over 26 weeks of treatment for Study 1. The x-axis represents weeks during treatment (0 to 26), and the y-axis shows mean change from baseline ADAS-cog rating, from -2 to 5. Three groups are compared: 6 to 12 mg, 1 to 4 mg, and placebo. The plot indicates clinical improvement is above baseline, clinical decline below, with error bars for each point.*

FDA Label Image

Package Label-principal Display Panel (1.5 mg Blister Carton (10 x 10 Unit-dose))

Packaging label for Rivastigmine Tartrate Capsules, USP 1.5 mg by Aurobindo Pharma Limited. The label shows a box for 100 (10 x 10) unit-dose capsules intended for prescription use only. The design includes the dosage strength highlighted in an orange oval and the labeler's logo with manufacturing details.*

FDA Label Image

Package Label-principal Display Panel (3 mg (60 Capsules Bottle))

Label for Rivastigmine Tartrate Capsules, USP 3 mg by Aurobindo Pharma Limited. The label states each capsule contains Rivastigmine tartrate USP equivalent to 3 mg rivastigmine. The package contains 60 capsules, with storage instructions and distributor information for Aurobindo Pharma USA, Inc. A barcode and NDC 65862-649-60 are also visible.*

FDA Label Image

Package Label-principal Display Panel (3 mg Blister Carton (10 x 10 Unit-dose))

Packaging label for Rivastigmine Tartrate Capsules, USP 3 mg by Aurobindo Pharma Limited. The box contains 100 (10 x 10) unit-dose capsules. The label prominently displays the drug name, strength (3 mg), and dosage form. The NDC number 65862-649-78 is also visible on the label.*

FDA Label Image

Package Label-principal Display Panel (4.5 mg (60 Capsules Bottle))

Label for Rivastigmine Tartrate Capsules USP, 4.5 mg strength, with a count of 60 capsules. The label shows the NDC 65862-650-60 and is marked Rx only. Distributed by Aurobindo Pharma USA, Inc., made in India. The label includes storage instructions, dosage note, and warnings to keep out of reach of children.*

FDA Label Image

Package Label-principal Display Panel (4.5 mg Blister Carton (10 x 10 Unit-dose))

Packaging label for Rivastigmine Tartrate Capsules USP 4.5 mg by Aurobindo Pharma Limited. The label shows a carton design for 100 (10 x 10) unit-dose capsules with the strength prominently displayed in green. The label includes product name, strength, unit count, and manufacturer details along with the NDC number 65862-650-78.*

FDA Label Image

Package Label-principal Display Panel (6 mg (60 Capsules Bottle))

Rivastigmine Tartrate Capsules, USP 6 mg capsule label by Aurobindo Pharma Limited. The label indicates 60 capsules per container, with storage instructions at 20° to 25°C. It includes manufacturer information, NDC 65862-651-60, and cautions to keep out of reach of children. Distributed by Aurobindo Pharma USA, Inc.*

FDA Label Image

Package Label-principal Display Panel (6 mg Blister Carton (10 x 10 Unit-dose))

Packaging label for Rivastigmine Tartrate Capsules USP, 6 mg strength. The label indicates a unit-dose capsule format with 100 capsules per package (10 x 10). The labeler is Aurobindo Pharma Limited, and the product is identified by NDC 65862-651-78. The label features the product name, strength in a blue oval, and directions for storage and handling instructions.*

FDA Label Image

Figure 2 (Rivastigmine Fig2)

A cumulative percentage graph showing patients completing 26 weeks of double-blind treatment with changes from baseline ADAS-cog scores. The chart compares placebo, 1 to 4 mg/day, and 6 to 12 mg/day treatment groups, with cumulative percentage of patients on the vertical axis and change from baseline on the horizontal axis. An inset table summarizes score changes by treatment group.*

FDA Label Image

Figure 3 (Rivastigmine Fig3)

A bar graph illustrating the frequency distribution of CIBIC-Plus scores at Week 26 from Study 1. It compares percentages of patients across different CIBIC-Plus rating categories (Markedly Improved to Markedly Worse) among three groups: Placebo, 1 to 4 mg, and 6 to 12 mg dosages.*

FDA Label Image

Figure 4 (Rivastigmine Fig4)

A line graph illustrating the time-course change from baseline in ADAS-cog scores over 26 weeks for patients treated with 6 to 12 mg, 1 to 4 mg, or placebo. The vertical axis shows mean change in ADAS-cog rating, with clinical improvement and decline indicated. The horizontal axis represents weeks during treatment (0, 12, 18, 26). Error bars represent standard error of the mean.*

FDA Label Image

Figure 5 (Rivastigmine Fig5)

A cumulative percentage graph showing patients completing 26 weeks of double-blind treatment with changes from baseline ADAS-cog scores. It compares treatment groups: 6 to 12 mg, 1 to 4 mg, and placebo. The x-axis represents change from baseline and the y-axis shows cumulative percentage of patients. Included is a data table summarizing ADAS-cog score changes for each group (-7, -4, 0 points).*

FDA Label Image

Figure 6 (Rivastigmine Fig6)

A bar chart titled 'Frequency Distribution of CIBIC-Plus Scores at Week 26 in Study 2,' showing percentage of patients on the vertical axis and CIBIC-Plus ratings on the horizontal axis. The ratings range from Markedly Improved to Markedly Worse. The chart compares three groups: Placebo, 1 to 4 mg, and 6 to 12 mg, with bars indicating patient percentages for each CIBIC-Plus rating category.*

FDA Label Image

Figure 7 (Rivastigmine Fig7)

A line graph depicting the time course of change from baseline in ADAS-cog scores over 24 weeks of treatment. It compares Rivastigmine Tartrate and Placebo groups, showing mean change (+/- SEM) on the vertical axis and weeks during treatment on the horizontal axis. The graph highlights clinical improvement or decline during the study period.*

FDA Label Image

Figure 8 (Rivastigmine Fig8)

A bar chart titled 'Distribution of ADCS-CGIC Scores for Patients Completing 24 Weeks of Treatment in Study 4' compares Rivastigmine Tartrate and placebo groups. The x-axis shows ADCS CGI-C ratings from 'Markedly Improved' to 'Markedly Worse,' and the y-axis shows percentage of patients. The chart presents patient outcome distributions between the two groups across improvement and worsening categories.*

FDA Label Image

Package Label-principal Display Panel – 1.5 mg (60 Capsule Bottle) (Rivastigmine Fig9)

Label for Rivastigmine Tartrate Capsules USP 1.5 mg by Aurobindo Pharma Limited. The label states that each capsule contains Rivastigmine tartrate USP equivalent to rivastigmine 1.5 mg. It includes storage instructions, distributor information for Aurobindo Pharma USA, and cautions to dispense in a tight container and keep out of reach of children. The package contains 60 capsules.*

FDA Label Image

Chemical Structure (Rivastigmine Str)

Chemical structure of Rivastigmine Tartrate depicted with detailed atomic connectivity and presence of a tartrate moiety (C4H6O6). The image shows the 2D molecular formula highlighting the acetyl, methyl, and amine groups characteristic of this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.